BLPH vs. ADTX, EVFM, SXTC, SBFM, EVLO, SPRC, ATHX, APVO, AMPE, and CMRA
Should you be buying Bellerophon Therapeutics stock or one of its competitors? The main competitors of Bellerophon Therapeutics include Aditxt (ADTX), Evofem Biosciences (EVFM), China SXT Pharmaceuticals (SXTC), Sunshine Biopharma (SBFM), Evelo Biosciences (EVLO), SciSparc (SPRC), Athersys (ATHX), Aptevo Therapeutics (APVO), Ampio Pharmaceuticals (AMPE), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical preparations" industry.
Bellerophon Therapeutics (NASDAQ:BLPH) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
10.6% of Bellerophon Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 5.2% of Bellerophon Therapeutics shares are owned by insiders. Comparatively, 1.2% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Bellerophon Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 3,471.43%. Aditxt has a consensus price target of $61.00, suggesting a potential upside of 2,818.66%. Given Bellerophon Therapeutics' higher possible upside, analysts plainly believe Bellerophon Therapeutics is more favorable than Aditxt.
Bellerophon Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -5,016.31%. Bellerophon Therapeutics' return on equity of -187.35% beat Aditxt's return on equity.
Bellerophon Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.
In the previous week, Aditxt had 2 more articles in the media than Bellerophon Therapeutics. MarketBeat recorded 3 mentions for Aditxt and 1 mentions for Bellerophon Therapeutics. Aditxt's average media sentiment score of 0.21 beat Bellerophon Therapeutics' score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.
Bellerophon Therapeutics has higher earnings, but lower revenue than Aditxt.
Bellerophon Therapeutics received 315 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 60.42% of users gave Bellerophon Therapeutics an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
Summary
Bellerophon Therapeutics beats Aditxt on 8 of the 15 factors compared between the two stocks.
Get Bellerophon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellerophon Therapeutics Competitors List
Related Companies and Tools
